Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

BackgroundWhile the benefit of adjuvant therapy is well established in patients with stage IIIB–IIID melanoma, its role in stage IIIA disease remains a matter of discussion. This subgroup is generally considered to be at lower risk of recurrence, whereas currently available treatments are associated...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Francesca Romana Di Pietro, Rosa Falcone, Sofia Verkhovskaia, Giulia Poti, Cristina Maria Failla, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Roberto Morese, Zorika Christiana Di Rocco, Gabriele Piesco, Paolo Chesi, Paolo Marchetti, Federica De Galitiis
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2026-04-01
Sarja:	Frontiers in Oncology
Aiheet:	adjuvant treatment BRAF mutation III stage melanoma neoadjuvant strategy
Linkit:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1775350/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!